ABSTRACT

Background: Elevated blood pressure is a major preventable cause of cardiovascular diseases. Alcohol consumption is a well-known risk factor of elevated blood pressure. The aldehyde dehydrogenase 2 (ALDH2) polymorphism is common in Eastern Asians, and inactive ALDH2 genotypes are associated with both avoiding alcohol consumption and aldehyde accumulation. Therefore, this study assessed the associations between alcohol consumption and hypertension and blood pressure according to the ALDH2 genotypes.

Methods: This study consists of 8,526 participants in the Dong-gu Study. Multivariate logistic regression was used to calculate the odds ratio (OR) according to alcohol consumption after stratifying by gender and ALDH2 genotypes. Multivariate linear regression was performed to estimate the systolic blood pressure (SBP) and diastolic blood pressure (DBP) according to the amount of alcohol consumed.

Results: In men, alcohol consumption was positively associated with both SBP and DBP in active ALDH2 carriers, but not in inactive ALDH2 carriers. In active ALDH2 carriers, compared to non-drinkers, the OR of hypertension was 1.16 (95% confidence interval [CI], 0.91 – 1.49) for < 1 drink/day, and 1.44 (95% CI, 1.15– 1.80) for ≥ 1 drink/day in men. With each 1 drink/day increase, SBP and DBP increased by 3 and 1 mmHg in men, respectively. There was no significant association between ALDH2 genotypes and hypertension and blood pressure in women.

Conclusion: ALDH2 genotype modified the association between alcohol consumption and blood pressure in men. There was a positive relationship between alcohol consumption and blood pressure in active ALDH2 carriers, but no significant relationship in inactive ALDH2 carriers.

Keywords: ALDH2; Polymorphism; Hypertension; Cohort Studies
INTRODUCTION

Elevated blood pressure is a major preventable cause for cardiovascular diseases, including ischemic heart disease, stroke, heart failure, atrial fibrillation, and peripheral arterial disease, and a leading cause of all-cause mortality worldwide. \(^1\) Lifestyle modification is important for the prevention and treatment of elevated blood pressure. This includes weight loss, \(^2\) increased physical activity, \(^3\) and reduced alcohol consumption, \(^4\) which can reduce cardiovascular disease risk.

Alcohol is mainly metabolized by alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase. There are genetic differences in these enzymes in different ethnic groups. The aldehyde dehydrogenase 2 (\(ALDH2\)) variant is common in East Asians, and the activity of \(ALDH2\) varies by about 3–5 fold according to rs671, \(^5\) a missense \(ALDH2\) mutation. Mutations in \(ALDH2\) are closely related to the avoidance of alcohol drinking. Inactive \(ALDH2\) causes alcohol flush reactions such as erythema, nausea, and rapid heart rate as a result of aldehyde accumulation after alcohol consumption. \(^6,7\) Active \(ALDH2\) carriers who do not develop alcohol flushing tend to be drinkers with a greater amount of alcohol intake. \(^8,10\)

Many previous studies have evaluated the association between the \(ALDH2\) rs671 polymorphism and blood pressure. \(^9,11-16\) In some studies, \(^9,11,12,14,16\) the \(ALDH2\) genotype was considered as an instrumental variable of alcohol consumption. However, the \(ALDH2\) genotype modifies the effects of alcohol via aldehyde accumulation. Therefore, it is necessary to evaluate the relationship between alcohol consumption and blood pressure through stratification analyses according to the \(ALDH2\) genotype. In this study, we evaluated the associations between alcohol consumption and blood pressure and hypertension after stratifying the \(ALDH2\) genotype.

METHODS

Study population
This study was based on the Dong-gu Study, the framework of which has been described elsewhere. \(^17\) Briefly, the Dong-gu Study involved 9,260 participants aged ≥ 50 years who live in Gwangju, the metropolitan city in Korea. Of these, 495 participants with myocardial infarction or stroke were excluded. \(ALDH2\) genotyping was missing for 31 participants and information on alcohol consumption was missing for 131 participants. Ultimately, 8,526 participants without missing values were included in the analyses.

Blood pressure measurement and definition of hypertension
Blood pressure was measured by trained investigators three times at the right upper arm using a mercury sphygmomanometer after the participants had rested for ≥ 5 minutes. We used the mean of the three blood pressure measurements in the analyses. Hypertension was defined as either systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg or taking antihypertensive medication.

Assessment of lifestyles and comorbidities
Information on variables such as lifestyle and disease history was obtained through interview questionnaires. The frequency and amount per occasion of alcohol consumption were investigated; a non-drinker was defined as a participant who consumed less than one drink
per month. Alcohol consumption was coded as non-drinker, less than one standard drink per day, or one or more standard drinks per day. Smoking status was coded as never, ex-smoker, or current smoker. Physical activity was coded as walking for at least 30 minutes on at least 5 days per week or not. Body mass index (BMI) was calculated in kilograms per meter squared from weight and height measured in a standing position without shoes. A history of diabetes was assessed using questionnaires.

**Genotyping**
Genomic DNA was extracted from peripheral blood using a QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA, USA), according to the manufacturer’s protocol. rs671 was genotyped by high-resolution melting (HRM) analyses, using a Rotor-Gene 6000TM (Corbett Research, Sydney, Australia). The forward primer (5′-TTGGTGCTACAAGATGTCG-3′) and reverse primer (5′-CAGGTCCCACACTCACAGTTT-3′) primers producing a 97-bp amplicon. The reaction mixture for HRM included 200 nM PCR primers, 1 µM SYTO 9 fluorescent dye (Invitrogen, Carlsbad, CA, USA), 0.5U F-Star Taq DNA polymerase (BioFACT), and 40 ng genomic DNA in 10 µL reaction volumes. The cycling conditions comprised an initial denaturation at 95°C for 5 minutes, followed by 40 cycles of 95°C for 5 seconds and 58°C for 30 seconds.

**Statistical analysis**
The baseline characteristics of the study population are presented according to gender and ALDH2 genotype. General characteristics are expressed as means ± standard deviations or number (%). The general characteristics of the participants were compared using t-tests for continuous variables, and χ² tests for categorical data. Genotype was categorized as active ALDH2 (GG) and inactive ALDH2 (GA/AA). All analyses were carried out by gender. Multivariate linear regression was performed to assess the associations between ALDH2 and alcohol consumption and SBP and DBP. Multivariate logistic regression was performed to assess the associations between ALDH2 genotypes and alcohol consumption and hypertension.

**Ethics statement**
This study was approved by the Institutional Review Board (IRB) of Chonnam National University Hospital (IRB No. I-2008-05-056), and informed consent was obtained from each subject.

**RESULTS**
Table 1 shows the baseline characteristics according to the ALDH2 genotype and gender. The GG, GA, and AA genotype frequencies were 69.0%, 28.4%, and 2.6%, respectively, and were in Hardy–Weinberg equilibrium (P = 0.141). Inactive ALDH2 carriers were significantly older and had a lower alcohol consumption and lower DBP than active ALDH2 carriers in both genders. They had a lower BMI and SBP and a higher prevalence of hypertension, and diabetes only in men.

Table 2 shows the odds ratios (ORs) for hypertension in participants who were inactive ALDH2 carriers compared to active ALDH2 carriers. In the crude model, the ORs in men and women were 1.27 (95% confidence interval [CI], 1.10-1.47) and 1.04 (95% CI, 0.92-1.17), respectively. After adjusting for age, the risk difference was greater in model 1, and the ORs were 1.34 (95% CI, 1.16-1.56) in men and 1.09 (95% CI, 0.96-1.23) in women. In the final model, the ORs were 1.24 (95% CI, 1.06-1.45) in men and 1.08 (95% CI, 0.95-1.22) in women.
Table 1. General characteristics of study subjects according to genotype of ALDH2 rs671

| Characteristics       | GG          | GA/AA       | P value | GG          | GA/AA       | P value |
|------------------------|-------------|-------------|---------|-------------|-------------|---------|
| Total                  | 2,242 (67.6)| 1,077 (32.4)| < 0.001| 3,638 (69.9)| 1,569 (30.1)| 0.005   |
| Age, yr                | 65.6 ± 8.0  | 67.0 ± 7.9  |         | 64.1 ± 8.3  | 64.8 ± 8.3  |         |
| Smoking status         |             |             | 0.569   |             |             | 0.020   |
| Never smoker           | 570 (25.4)  | 283 (26.3)  |         | 3,491 (96.0)| 1,530 (97.5)|         |
| Ex-smoker              | 1,116 (49.8)| 515 (47.8)  |         | 67 (1.8)    | 19 (1.2)    |         |
| Current smoker         | 556 (24.8)  | 279 (25.9)  |         | 80 (2.1)    | 20 (1.3)    |         |
| Physical activity      | 601 (26.8)  | 272 (25.3)  | 0.342   | 465 (12.8)  | 202 (12.9)  | 0.927   |
| Alcohol consumption, drink/day |         |             | < 0.001|             |             | < 0.001 |
| Non-drinker            | 535 (23.9)  | 686 (63.7)  |         | 2,789 (76.7)| 1,475 (94.0)|         |
| < 1                    | 589 (26.3)  | 271 (25.2)  |         | 716 (19.7)  | 85 (5.4)    |         |
| ≥ 1                    | 1,118 (49.9)| 120 (11.1)  |         | 133 (3.7)   | 9 (0.6)     |         |
| Drinks/day             | 2.0 (2.6)   | 0.4 (1.1)   | < 0.001| 0.1 (0.5)   | 0.0 (0.2)   | < 0.001 |
| Hypertension           | 1,048 (46.7)| 440 (40.9)  | < 0.001| 1,559 (42.9)| 657 (41.9)  | 0.512   |
| Diabetes               | 576 (25.7)  | 184 (77.1)  | < 0.001| 563 (15.5)  | 238 (15.2)  | 0.778   |
| BMI, kg/m²             | 24.0 ± 2.8  | 23.6 ± 2.8  | < 0.001| 24.6 ± 3.0  | 24.6 ± 2.9  | 0.399   |
| SBP, mmHg              | 125.6 ± 16.4| 122.5 ± 16.8| < 0.001| 122.4 (17.0)| 122.0 (16.7)| 0.451   |
| DBP, mmHg              | 76.0 ± 10.6 | 74.6 ± 10.5 | < 0.001| 73.8 (9.9)  | 72.9 (9.9)  | 0.003   |

All values are given as mean ± standard deviation or number (%).
ALDH2 = aldehyde dehydrogenase 2, BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure.

Table 2. Association between ALDH2 rs671 polymorphism and HTN according to gender

| Variables | HTN (−) | HTN (+) | Crude model | Model 1 | Model 2 | P for interactiona |
|-----------|---------|---------|-------------|---------|---------|-------------------|
| Men       |         |         |             |         |         |                   |
| GG        | 1,194 (65.2)| 1,048 (70.4)| 1.27 (1.10–1.47)| 1.34 (1.16–1.56)| 1.24 (1.06–1.45)|         |
| GA/AA     | 637 (34.8)| 440 (29.6)| 1 (Ref.)    | 1 (Ref.) | 1 (Ref.) | 1.116             |
| Women     |         |         |             |         |         |                   |
| GG        | 2,079 (69.5)| 1,559 (70.4)| 1.04 (0.92–1.17)| 1.09 (0.96–1.23)| 1.08 (0.95–1.22)|         |
| GA/AA     | 912 (30.5)| 657 (29.6)| 1 (Ref.)    | 1 (Ref.) | 1 (Ref.) | 0.116             |

All values are given as odds ratio (95% confidence interval) or number (%).
ALDH2 = aldehyde dehydrogenase 2, HTN = hypertension.

aP value for interaction term between gender and ALDH2 rs671 genotype in model 2.

Table 3 shows the SBP and DBP according to ALDH2 genotypes and gender. The association between SBP and ALDH2 genotype was modified by gender (P for interaction = 0.002). In men, inactive ALDH2 carriers had a lower SBP and DBP, while in women, SBP did not differ significantly according to ALDH2 genotype, and inactive ALDH2 carriers genotype had a lower DBP.

Table 3. Association between ALDH2 rs671 polymorphism and blood pressure according to gender

| Variables | SBP | DBP |
|-----------|-----|-----|
|           | Crude | Model 1 | Model 2 | Crude | Model 1 | Model 2 |
| Men       |       |        |        |       |        |        |
| GG        | 125.6 ± 0.4| 125.7 ± 0.3| 125.6 ± 0.4| 76.0 ± 0.2| 76.0 ± 0.2| 76.0 ± 0.2|
| GA/AA     | 122.5 ± 0.5| 122.2 ± 0.5| 122.5 ± 0.5| 74.6 ± 0.3| 74.6 ± 0.3| 74.6 ± 0.3|
| P value   | < 0.001| < 0.001| < 0.001| < 0.001| < 0.001| < 0.001|
| Women     |       |        |        |       |        |        |
| GG        | 122.4 ± 0.3| 122.5 ± 0.3| 122.4 ± 0.3| 73.8 ± 0.2| 73.8 ± 0.2| 73.8 ± 0.2|
| GA/AA     | 122.0 ± 0.4| 121.8 ± 0.4| 121.8 ± 0.4| 72.9 ± 0.3| 73.0 ± 0.3| 73.0 ± 0.3|
| P value   | 0.451| 0.155| 0.196| 0.003| 0.007| 0.009|

P for interaction* | 0.002 | 0.537

All values are given as adjusted mean ± standard error.
ALDH2 = aldehyde dehydrogenase 2, SBP = systolic blood pressure, DBP = diastolic blood pressure.

*P value for interaction term between gender and ALDH2 rs671 genotype in model 2.
Table 4 shows the association between alcohol consumption and the risk of hypertension according to ALDH2 genotypes and gender. The association between alcohol consumption and risk of hypertension was only significant in men who had the active ALDH2 genotype, while not significant in women.

Table 5 shows the dose-response relationship between alcohol consumption and blood pressure for each ALDH2 genotype. The ALDH2 genotype modified the association between alcohol consumption and SBP ($P$ for interaction $<0.001$) and DBP ($P$ for interaction $=0.007$) in men, but not in women. The association between alcohol consumption and blood pressure was not significant in women, while in men, both SBP and DBP increased with alcohol consumption in the active ALDH2 carrier. By contrast, the inactive ALDH2 carrier was not related to alcohol consumption or blood pressure.

### Table 4. Association between alcohol consumption and HTN, stratified by gender and ALDH2 rs671 genotype

| Variables | Men | | | | Women | | | |
|-----------|-----|-------|-------|----------------|-------|-------|-------|-------|
| | HTN (−) | HTN (+) | OR (95% CI) | HTN (−) | HTN (+) | OR (95% CI) |
| GG genotype | | | | | | | | |
| Non-drinker | 304 (56.8) | 231 (43.2) | 1 (Ref.) | 1,573 (56.4) | 1,216 (43.6) | 1 (Ref.) |
| Current drinker, drink/day | | | | | | | | |
| < 1 | 316 (53.7) | 273 (46.3) | 1.33 (1.08–1.64) | 506 (59.6) | 434 (60.6) | 1.16 (0.91–1.49) |
| ≥ 1 | 574 (51.3) | 544 (48.7) | 1.44 (1.15–1.80) | 72 (54.1) | 61 (45.9) | 1.30 (0.90–1.87) |
| $P$ value for trenda | 0.001 | | | 0.344 |
| GA/AA genotype | | | | | | | | |
| Non-drinker | 404 (58.9) | 282 (41.1) | 1 (Ref.) | 851 (57.7) | 624 (42.3) | 1 (Ref.) |
| Current drinker, drink/day | | | | | | | | |
| < 1 | 233 (59.6) | 158 (40.4) | 1.12 (0.85–1.46) | 61 (64.9) | 33 (35.1) | 1.02 (0.64–1.63) |
| ≥ 1 | 163 (60.1) | 108 (39.9) | 1.05 (0.77–1.42) | 55 (64.7) | 30 (35.3) | 1.00 (0.61–1.64) |
| $P$ value for trenda | 0.279 | | | 0.874 |

All models were adjusted for age, smoking history, physical activity, diabetes mellitus, and body mass index. ALDH2 = aldehyde dehydrogenase 2, HTN = hypertension, OR = odds ratio, CI = confidence interval.

aTrend test from non-drinker, < 1 drink/day, to ≥ 1 drink/day; b $P$ value for interaction term between alcohol consumption (non-drinker and current drinker) and ALDH2 rs671 genotype.

### Table 5. Association between alcohol consumption and blood pressure, stratified by ALDH2 rs671 genotype

| Variables | Men | | | | Women | | | |
|-----------|-----|-------|-----|-------|-------|-------|-----|
| | No. | SBP, mmHg | DBP, mmHg | | No. | SBP, mmHg | DBP, mmHg |
| GG genotype | | | | | | | | |
| Non-drinker | 535 (23.9) | 121.9 ± 0.7 | 74.3 ± 0.4 | 2,789 (76.7) | 122.3 ± 0.3 | 73.7 ± 0.2 |
| Current drinker, drink/day | 1,707 (76.1) | 126.7 ± 0.4 | 76.5 ± 0.2 | 849 (23.3) | 122.6 ± 0.6 | 74.2 ± 0.3 |
| < 1 | 589 (26.3) | 125.1 ± 0.7 | 75.6 ± 0.4 | 716 (73.7) | 122.2 ± 0.6 | 74.0 ± 0.4 |
| ≥ 1 | 1,118 (49.9) | 127.6 ± 0.5 | 77.1 ± 0.3 | 133 (3.7) | 124.3 ± 1.4 | 75.0 ± 0.8 |
| $P$ value for trenda | < 0.001 | < 0.001 | 0.247 | 0.791 |
| GA/AA genotype | | | | | | | | |
| Non-drinker | 686 (63.7) | 122.6 ± 0.6 | 74.4 ± 0.4 | 1,475 (94.0) | 121.8 ± 0.4 | 72.9 ± 0.2 |
| Current drinker, drink/day | 391 (36.3) | 122.4 ± 0.8 | 74.8 ± 0.5 | 94 (6.0) | 125.1 ± 1.7 | 74.2 ± 1.0 |
| < 1 | 271 (25.2) | 122.3 ± 1 | 74.6 ± 0.6 | 85 (5.4) | 125.0 ± 1.8 | 74.3 ± 1.1 |
| ≥ 1 | 120 (11.1) | 122.7 ± 1.5 | 75.1 ± 0.9 | 9 (0.6) | 126.2 ± 5.4 | 72.9 ± 3.2 |
| $P$ value for trenda | 0.954 | 0.530 | 0.055 | 0.269 |
| $P$ for interactiona | < 0.001 | 0.007 | 0.112 | 0.488 |

Values are adjusted mean ± standard error after adjusting for age, smoking history, physical activity, diabetes mellitus, and body mass index. ALDH2 = aldehyde dehydrogenase 2, SBP = systolic blood pressure, DBP = diastolic blood pressure.

aTrend test from non-drinker, < 1 drink/day, to ≥ 1 drink/day; b $P$ value for interaction term between alcohol consumption (non-drinker and current drinker) and ALDH2 rs671 genotype.
DISCUSSION

In this study, active ALDH2 carriers were associated with a high risk of hypertension in men. The association between alcohol consumption and SBP was dose-dependent in active ALDH2 carriers. However, there was no significant association between the ALDH2 polymorphism and hypertension and blood pressure in women.

In previous studies, active ALDH2 carriers had a higher risk for hypertension than inactive ALDH2 carriers. The difference in blood pressure according to the activity of ALDH2 can be explained by the difference in alcohol consumption. In previous studies, active ALDH2 carriers included a high prevalence of drinkers or greater alcohol consumption. In our study, compared to inactive ALDH2 carriers, active ALDH2 carriers have 1.7 more drinks per day in men. In women, however, the amount of alcohol consumption was so small that the difference in consumption by the ALDH2 genotype was not significant. By contrast, Zhang et al. found no significant association between ALDH2 genotype and blood pressure in both never and current drinkers. In their study, there was an overadjustment bias due to the unnecessary adjustment of the frequency of alcohol consumption, an intermediate variable, in the association between ALDH2 genotype and blood pressure. In our study, active ALDH2 carriers had a 3.1 mmHg higher SBP and 1.4 mmHg higher DBP than inactive ALDH2 carriers in men. Ota et al. reported a 3.3 mmHg higher SBP and 2.6 mmHg higher DBP in active ALDH2 carriers compared to inactive ALDH2 carriers. In the study of Isomura et al., the SBP and DBP of active ALDH2 carriers were 1.8 and 1.3 mmHg higher than those of inactive ALDH2 carriers, respectively. We also found a dose-response relationship between alcohol consumption and blood pressure in active ALDH2 carriers. Similarly, meta-analysis studies of observational studies and clinical trials found a positive dose-response relationship between the amount of alcohol consumption and incidence of hypertension, and reducing alcohol consumption led to lower blood pressure. Chronic alcohol consumption increases blood pressure via increased sympathetic nerve activity, reduced antioxidants, and impaired vascular relaxation.

In our study, the ALDH2 genotype modified the association between alcohol consumption and blood pressure. There were dose-response relationships between alcohol consumption and SBP and DBP in active ALDH2 carriers, but no significant relationship in inactive ALDH2 carriers. In inactive ALDH2 carriers, it is not clear why blood pressure did not increase with the amount of alcohol consumption. Based on our results, we postulate that other blood pressure lowering effects of ethanol metabolites, such as aldehyde, counteract the ethanol-induced blood pressure increase. After alcohol consumption, inactive ALDH2 carriers have a fivefold higher peak blood aldehyde level than active ALDH2 carriers. Aldehyde lowers blood pressure in the early phase after drinking alcohol. In an animal study, an inactive ALDH2-like disulfiram-treated group had a lower blood pressure than a control group after ethanol administration. Few studies have evaluated the dose-response relationship between alcohol consumption and blood pressure according to the ALDH2 genotype. In contrast with our results, Ota et al. reported a significant positive association between the amount of alcohol consumption and SBP only in inactive ALDH2 carriers. However, their study population was small and consisted of only men workers with high alcohol consumption.

In inactive ALDH2 carriers, the difference in the amount of alcohol consumption among categories of alcohol consumption was not sufficiently large, so the association between alcohol consumption and blood pressure may not have been evaluated sufficiently. Drinkers
who are inactive ALDH2 carriers consume less alcohol than drinkers who are active ALDH2 carriers. Because the difference in alcohol consumption between drinkers and non-drinkers in the inactive ALDH2 carrier is less than that of the active ALDH2 carrier, the effects of drinking on the increase in blood pressure were weak in inactive ALDH2 carriers. In our study, of those who drank more than one drink per day, those with the inactive ALDH2 genotype drank 2.88 drinks per day, whereas those with the active ALDH2 genotype had 3.89 drinks per day. The binge-drinking rate was 64.5% in the drinkers with the active ALDH2 genotype, but 28.5% in those with the inactive genotype (data not shown).

The main strength of our study was the large sample size, which enabled us to evaluate the association between alcohol consumption and blood pressure according to ALDH2 genotypes. The limitation of our study is that other polymorphisms affecting alcohol metabolism, such as ADH 1B (ADH1B), were not evaluated in this study. However, ADH1B polymorphism was not significantly associated with a high risk of hypertension or high blood pressure in previous studies.

In conclusion, there was a positive dose-response relationship between alcohol consumption and blood pressure in active, but not in inactive, ALDH2 carriers. Further studies are needed to clarify the mechanism of effect modification of the ALDH2 rs671 polymorphism on the association between alcohol intake and blood pressure.

REFERENCES

1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. *JAMA* 2017;317(2):165-82. [PUBMED](https://doi.org/10.1001/jama.2016.18697) [CROSSREF](https://doi.org/10.1001/jama.2016.18697)

2. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The trials of hypertension prevention, phase II. The trials of hypertension prevention collaborative research group. *Arch Intern Med* 1997;157(6):657-67. [PUBMED](https://doi.org/10.1001/archinte.1997.00410060082007) [CROSSREF](https://doi.org/10.1001/archinte.1997.00410060082007)

3. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. *Ann Intern Med* 2002;136(7):493-503. [PUBMED](https://doi.org/10.1059/1526-5371-36.7.493) [CROSSREF](https://doi.org/10.1059/1526-5371-36.7.493)

4. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. *Lancet Public Health* 2017;2(2):e108-20. [PUBMED](https://doi.org/10.1016/S2468-2667(16)30028-2) [CROSSREF](https://doi.org/10.1016/S2468-2667(16)30028-2)

5. Seitz HK, Mueller S. Alcohol and cancer. In: Verster JC, Brady K, Galanter M, Conrod P, editors. *Drug Abuse and Addiction in Medical Illness: Causes, Consequences and Treatment*. New York, NY: Springer; 2012, 431-41.

6. Maejima R, Iijima K, Kaitovaara P, Hatta W, Koike T, Imatani A, et al. Effects of ALDH2 genotype, PPI treatment and L-cysteine on carcinogenic acetaldehyde in gastric juice and saliva after intragastric alcohol administration. *PLoS One* 2015;10(4):e0120397. [PUBMED](https://doi.org/10.1371/journal.pone.0120397) [CROSSREF](https://doi.org/10.1371/journal.pone.0120397)

7. Yokoyama A, Tsutsuki E, Imazeki H, Suwa Y, Nakamura C, Mizukami T, et al. Salivary acetaldehyde concentration according to alcoholic beverage consumed and aldehyde dehydrogenase-2 genotype. *Alcohol Clin Exp Res* 2008;32(9):1607-14. [PUBMED](https://doi.org/10.1111/j.1530-0282.2008.00877.x) [CROSSREF](https://doi.org/10.1111/j.1530-0282.2008.00877.x)

8. Quillen EE, Chen XD, Almasy L, Yang F, He H, Li X, et al. ALDH2 is associated to alcohol dependence and is the major genetic determinant of “daily maximum drinks” in a GWAS study of an isolated rural Chinese sample. *Am J Med Genet B Neuropsychiatr Genet* 2014;165B(2):103-40. [PUBMED](https://doi.org/10.1002/ajmg.b.32373) [CROSSREF](https://doi.org/10.1002/ajmg.b.32373)

9. Cho Y, Kwak S, Lewis SJ, Wade KH, Relton CL, Smith GD, et al. Exploring the utility of alcohol flushing as an instrumental variable for alcohol intake in Koreans. *Sci Rep* 2018;8(1):458. [PUBMED](https://doi.org/10.1038/s41598-017-17846-z) [CROSSREF](https://doi.org/10.1038/s41598-017-17846-z)
10. Takeuchi F, Isono M, Nabika T, Katsuya T, Sugiyama T, Yamaguchi S, et al. Confirmation of ALDH2 as a major locus of drinking behavior and of its variants regulating multiple metabolic phenotypes in a Japanese population. *Circ J* 2011;75(4):911-8.

11. Ma C, Yu B, Zhang W, Wang W, Zhang L, Zeng Q. Associations between aldehyde dehydrogenase 2 (ALDH2) rs671 genetic polymorphisms, lifestyles and hypertension risk in Chinese Han people. *Sci Rep* 2017;7(1):11136.

12. Isomura M, Wang T, Yamasaki M, Hasan MZ, Shiwaku K, Nabika T. Aldehyde dehydrogenase polymorphisms and blood pressure elevation in the Japanese: a cross-sectional and a longitudinal study over 20 years in the Shimane CoHRE study. *Dis Markers* 2015;2015:825435.

13. Yokoyama A, Mizukami T, Matsui T, Yokoyama T, Kimura M, Matsushita S, et al. Genetic polymorphisms of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 and liver cirrhosis, chronic calcific pancreatitis, diabetes mellitus, and hypertension among Japanese alcoholic men. *Alcohol Clin Exp Res* 2013;37(8):1391-401.

14. Zhang WS, Xu L, Schooling CM, Jiang CQ, Cheng KK, Liu B, et al. Effect of alcohol and aldehyde dehydrogenase gene polymorphisms on alcohol-associated hypertension: the Guangzhou Biobank Cohort Study. *Hypertens Res* 2013;36(8):741-6.

15. Ota M, Hisada A, Lu X, Nakashita C, Masuda S, Katoh T. Associations between aldehyde dehydrogenase 2 (ALDH2) genetic polymorphisms, drinking status, and hypertension risk in Japanese adult male workers: a case-control study. *Environ Health Prev Med* 2016;21(1):1-8.

16. Chen L, Smith GD, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a mendelian randomization approach. *PLoS Med* 2008;5(3):e52.

17. Kweon SS, Shin MH, Jeong SK, Nam HS, Lee YH, Park KS, et al. Cohort profile: the Namwon study and the Dong-gu Study. *Int J Epidemiol* 2014;43(2):558-67.

18. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. *Epidemiology* 2009;20(4):488-95.

19. Roerecke M, Tobe SW, Kaczorowski J, Bacon SL, Vafaei A, Hasan OS, et al. Sex-specific associations between alcohol consumption and incidence of hypertension: a systematic review and meta-analysis of cohort studies. *J Am Heart Assoc* 2018;7(13):e008202.

20. Marchi KC, Muniz JJ, Tirapelli CR. Hypertension and chronic ethanol consumption: what do we know after a century of study? *World J Cardiol* 2014;6(5):283-94.

21. Hellström E, Tottmar O. Acute effects of ethanol and acetaldehyde on blood pressure and heart rate in disulfiram-treated and control rats. *Pharmacol Biochem Behav* 1982;17(6):1103-9.